RTW Investments LP Makes New $11.71 Million Investment in COMPASS Pathways plc (NASDAQ:CMPS)

RTW Investments LP bought a new stake in COMPASS Pathways plc (NASDAQ:CMPS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 3,098,987 shares of the company's stock, valued at approximately $11,714,000. RTW Investments LP owned approximately 4.53% of COMPASS Pathways as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in CMPS. Point72 Asset Management L.P. lifted its stake in COMPASS Pathways by 15.4% during the fourth quarter. Point72 Asset Management L.P. now owns 67,999 shares of the company's stock worth $257,000 after purchasing an additional 9,099 shares during the last quarter. Integral Health Asset Management LLC acquired a new stake in shares of COMPASS Pathways during the fourth quarter worth $756,000. Cubist Systematic Strategies LLC lifted its position in shares of COMPASS Pathways by 205.7% in the 4th quarter. Cubist Systematic Strategies LLC now owns 126,636 shares of the company's stock worth $479,000 after buying an additional 85,213 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of COMPASS Pathways in the 4th quarter valued at about $2,458,000. Finally, Jane Street Group LLC grew its position in shares of COMPASS Pathways by 72.7% during the 4th quarter. Jane Street Group LLC now owns 51,815 shares of the company's stock valued at $196,000 after buying an additional 21,815 shares during the last quarter. 46.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CMPS has been the topic of a number of recent research reports. Cantor Fitzgerald raised shares of COMPASS Pathways to a "strong-buy" rating in a report on Tuesday, May 13th. Canaccord Genuity Group cut their price target on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, February 28th. Stifel Nicolaus began coverage on COMPASS Pathways in a research note on Thursday, February 27th. They set a "buy" rating and a $11.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and set a $45.00 price objective on shares of COMPASS Pathways in a research note on Monday, May 12th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $20.20.

COMPASS Pathways Stock Performance

Shares of CMPS traded up $0.37 during mid-day trading on Monday, reaching $4.35. 1,974,351 shares of the company's stock traded hands, compared to its average volume of 810,676. The business's 50-day moving average price is $3.35 and its 200-day moving average price is $3.93. The stock has a market capitalization of $403.89 million, a P/E ratio of -1.98 and a beta of 2.27. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. COMPASS Pathways plc has a 12 month low of $2.49 and a 12 month high of $8.54.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.03. Equities analysts predict that COMPASS Pathways plc will post -2.33 earnings per share for the current year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.